ABAnouk Boudewijn

Anouk Boudewijn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anouk Boudewijn has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patients with angina and non-obstructive coronary artery disease undergoing comprehensive invasive coronary function testing: long-term clinical outcomes

    by Caïa Crooijmans, Fleur W Adriaansen, Joan G Meeder, Marcel A M Beijk, Behruz Yosofi, Yolande Appelman, Aimane Mechroubi, Annemiek de Vos, Valeria Paradies, Martijn Meuwissen, et al.

    Background and Aims: Comprehensive evaluation by invasive coronary function test (CFT) of patients with angina and non-obstructive coronary artery disease is recommended in the current guidelines. The prognosis of patients with CFT-proven coronary vasomotor dysfunction (CVDys) is less well-known. Methods: Patients that provided consent for the previously published NL-CFT registry who underwent clinically indicated invasive CFT between 1 February 2019 and 1 June 2024 were included. Patients with CVDys, defined as an abnormal spasm provocation test and/or microvascular functional assessment, were compared to patients with normal CFT. The primary outcome of major adverse cardiovascular events and emergency room visits for angina (MACE-EA) was defined as a composite of all-cause death, acute coronary syndrome, stroke/transient ischaemic attack, revascularization, repeat angiography without intervention, heart failure hospitalizations, and unplanned hospitalizations or emergency room visits due to angina. Results: In total, 1355 patients were included. In 79.8%, CFT was abnormal, and vasospasm was the most prevalent endotype. In 1252 patients, follow-up of clinical events was complete. During a mean follow-up of 33 ± 13 months, CVDys patients had almost double the number of primary outcome events compared with patients with a normal CFT (31.2% vs 16.8%, P < .001), driven by emergency care visits for angina. Secondary clinical endpoints including death, myocardial infarction, stroke, or revascularization were low and comparable between the groups. Conclusions: The long-term risk of MACE-EA is doubled in ANOCA patients with CFT-confirmed CVDys compared with normal CFT results. Events are dominated by emergency room visits due to angina, illustrating the high disease burden of CVDys. Their (angina-related) health status is significantly worse at follow-up.


  • Open Access

    In vitro protein digestibility and colonic fermentation of mycoprotein-based meat analogues

    by Renata M.C. Ariëns, Katarzyna Polanowska, Dianne Somhorst, Anouk Boudewijn, Laurice Pouvreau, Govardus A.H. de Jong, Shanna Bastiaan-Net


  • Open Access

    Ex vivo autologous immune cell assay to study modulation of type 2 Inflammation by processed- or novel food extracts in peanut allergy

    by Robine Janssen, Alinda J. Berends, Marit Zuurveld, Severina Terlouw, Govardus A.H. de Jong, Dianne B.P.M. Somhorst, Anouk Boudewijn, Sharon Veenbergen, Harry J. Wichers, Johan Garssen, et al.

    Peanut allergy represents a major food-allergy burden, raising concerns about food processing and novel dietary products. Current diagnostics assess primarily allergic endpoints rather than immune mechanisms initiating and maintaining type 2 inflammation, particularly DC2-mediated Th2 polarization. Here, an ex vivo autologous type 2 inflammatory monocyte-derived dendritic cell (moDC) DC2/T cell and B cell assay has been introduced enabling to study immunomodulatory effects induced by unprocessed (P-D) versus processed (P-DH (heated) or P-DHG (heated and glycated)) peanut proteins. Separately, different emerging food samples were assessed (protein concentrates or whole biomass) enabling to study their capacities to modify inflammatory DC2/T cell responses. CD14⁺ monocytes, CD4 + T cells and CD19⁺ B cells were isolated from six peanut-allergic patients’ PBMCs. MoDCs generated with IL4/GM-CSF were exposed (48h) to type 2 polarizing cytokine (DC2) mix, or DC2 mix combined with the food samples. Next, DC2s were co-cultured with T cells (5d), followed by B cells incubation with DC2/T cell supernatant and food samples (10d). Supernatants and cells were analyzed for Th1/Th2/Th-regulatory (Treg) cells, IgE and IgG profiles. DC2 induced a strong Th2 phenotype and activity, P-D DC2 further enhanced IL13 secretion and %Tregs. P-DH DC2 favored Th2, whereas P-DHG DC2 increased IFNγ, with neither increasing %Treg. P-D and P-DH DC2 increased CD40L + CD25 + memory Th2, and P-DHG showed the same tendency. Wheat, whey and seaweed biomass had little effect on DC2/Th2 driven type 2 inflammation at the dose studied, whereas algae showed distinct immunomodulatory, adjuvant-like activity upon co-exposure during inflammatory DC2 maturation. In conclusion, this autologous in vitro assay captures modification of type 2 inflammatory response in DC2-Th2 interaction, which can compile both allergen-specific and generic reactivity to food samples, supporting the potential future use of this assay as an additional tool to assess type 2-driving potential and possible allergenicity of emerging foods and processing methods in peanut-allergic patients. Graphical Immune cell and other illustration elements were adapted from (1, 2) and (54). Illustrations from (1, 2) were adapted with permission; permission conveyed through Copyright Clearance Center, Inc. Reference (1): © The Authors, published by Wiley-VCH GmbH under a CC BY-NC-ND license. Reference (2): © The Authors, published by Elsevier Ltd under a CC BY 4.0 license. Illustrations from (54) were adapted under the terms of the CC BY 4.0 license; © The Authors, published by Wiley-VCH GmbH. Capsule summary: The autologous moDC-T cell-B cell in vitro assay may be used to assess whether processing methods or new foods might have intrinsic capacity to affect type 2 inflammation in peanut-allergic patients.